{"id":949837,"date":"2026-04-08T08:35:05","date_gmt":"2026-04-08T12:35:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/"},"modified":"2026-04-08T08:35:05","modified_gmt":"2026-04-08T12:35:05","slug":"aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/","title":{"rendered":"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WAYNE, Pa., April  08, 2026  (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris\u2019 Chief Executive Officer Dr. Neal Walker and other members of Aclaris\u2019 senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.<\/p>\n<p>A live and archived webcast of this event will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XXrYA2FzZkOaQn8tSErHtpKbF2j2hZYd2Imqe8a82Tjn0CPmn4GWrf7qorvsiJoM8HL5G2iqwHx4HWV6dsnhAYao1lxe36JnpRC6ku3CeWs=\" rel=\"nofollow\" target=\"_blank\">Events page<\/a> of the Aclaris website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z3w-DscAc1CR3ckkEI5r_vpkqRRU1ZfblZkZRYSwGnIYXPEe25maViZKZY3IWaqUQMj_nzBHvVuP4HSTxI3PJDnx0fjiZmOXH4U-lM2B90M=\" rel=\"nofollow\" target=\"_blank\">www.aclaristx.com<\/a>. The webcast will be available on the Aclaris website for at least 30 days.<\/p>\n<p>\n        <strong>About Aclaris Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&amp;D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mguiRB79k5txSuyhRGBa3XtUxO5Pv7DMzq8lgwxsXV_J3KiYFcT7OTTHNtWlvgNjvbHYR8F8yf-UT78b3TMrUAaWejWntGPuWT6PGfqdt6UxBTqjNyDgZMAlwJpxpY3J\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Aclaris Therapeutics Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Will Roberts<\/strong><br \/>\n        <br \/>Senior Vice President<br \/>Corporate Communications and Investor Relations<br \/>(484) 329-2125<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BtLdC4iYGJioya1IxFMNt38walHraIMKFPt-a-goC_PP2V8fghvMgRHTdFYHH-L6-NmATPPkJN4GKRFAgoyIWm3CXU4lxdwgO98B5oScmJE=\" rel=\"nofollow\" target=\"_blank\">wroberts@aclaristx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzMyYmUwNDAtMzgxZi00NDBjLWJhZWItMWExOTNkYjVmYTExLTEwMzE3NTUtMjAyNi0wNC0wOC1lbg==\/tiny\/Aclaris-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris\u2019 Chief Executive Officer Dr. Neal Walker and other members of Aclaris\u2019 senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949837","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris\u2019 Chief Executive Officer Dr. Neal Walker and other members of Aclaris\u2019 senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of &hellip; Continue reading &quot;Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:35:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference\",\"datePublished\":\"2026-04-08T12:35:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/\"},\"wordCount\":196,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/\",\"name\":\"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=\",\"datePublished\":\"2026-04-08T12:35:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Market Newsdesk","og_description":"WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris\u2019 Chief Executive Officer Dr. Neal Walker and other members of Aclaris\u2019 senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of &hellip; Continue reading \"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T12:35:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference","datePublished":"2026-04-08T12:35:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/"},"wordCount":196,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/","name":"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=","datePublished":"2026-04-08T12:35:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTUyOCM3NTIzNjE5IzIwMjAxODM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949837"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949837\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}